Inflammatory Bowel Diseases: New Diagnostic and Therapeutic Approaches—Second Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 817

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Gastroenterology, Vila Nova de Gaia Espinho Hospital Center, Vila Nova de Gaia, Portugal
2. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal
Interests: inflammatory bowel disease; endoscopy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Gastroenterology, São João Hospital University Centre, Porto, Portugal
2. Unidade de Farmacologia Clínica, São João Hospital University Centre, Porto, Portugal
3. Unit of Pharmacology and Therapeutics, Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal
Interests: gastroenterology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are lifelong gastrointestinal tract disorders, whose prevalence is projected to reach 1% by 2030. The unpredictable remitting–relapsing course is a defining characteristic, significantly contributing to the burden of IBD. Remarkable advancements in the understanding of IBDs have been made in recent decades. It is now evident that IBDs arise from a complex interplay of genetic, environmental, and microbial factors, leading to dysregulated immune responses. However, there are still several unresolved aspects that limit timely diagnosis and therapeutic options, impacting patients' prognosis and quality of life. Therefore, it is crucial to encourage research that addresses the existing knowledge gaps. In this Special Issue, we invite original research or review articles focused on various topics related to IBD, including the following:

  • Mechanisms underlying IBD pathogenesis;
  • Disease monitoring;
  • Biomarkers;
  • Pharmacological innovations (new targets and combination therapy);
  • Endoscopic treatment;
  • Risk stratification and individualized therapy;
  • Management of extraintestinal manifestations;
  • Comorbidities in patients with IBD.

Dr. Maria Manuela Estevinho
Dr. Fernando Magro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bowel inflammation
  • Crohn’s disease
  • endoscopy
  • inflammatory bowel disease
  • targeted therapy
  • ulcerative colitis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 630 KiB  
Review
Unravelling the Link Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Literature Review
by Konstantinos Mpakogiannis, Fotios S. Fousekis, Emmanouil Karampinis, Eleftheria Mastoridou, Georgios Gaitanis and Konstantinos H. Katsanos
Biomedicines 2025, 13(8), 1833; https://doi.org/10.3390/biomedicines13081833 - 27 Jul 2025
Viewed by 640
Abstract
Hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, immune-mediated conditions with significant impact on quality of life. Emerging evidence reveals a notable epidemiological and pathogenic overlap between HS and IBD, particularly CD. Although [...] Read more.
Hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, immune-mediated conditions with significant impact on quality of life. Emerging evidence reveals a notable epidemiological and pathogenic overlap between HS and IBD, particularly CD. Although a bidirectional association between HS and IBD has been well documented, current evidence supports a causal effect of IBD on the development of HS, while a causal relationship in the opposite direction has yet to be established. The present review explores the important association between these immune-mediated conditions and further highlights shared risk factors, genetic predispositions and immunopathogenic mechanisms, such as dysbiosis and cytokine dysregulation, involved in both HS and IBD. Diagnostic challenges, especially in differentiating perianal HS from perianal CD, are also discussed. The coexistence of HS and IBD impacts disease severity, treatment response, and overall management strategies. Shared therapeutic approaches, such as TNF-α inhibitors and JAK inhibitors, are considered promising options for effectively managing patients affected by both conditions. Nevertheless, deeper understanding of the gut–skin axis that will offer potential for more precise interventions in patients with simultaneous HS and IBD is considered imperative. Full article
Show Figures

Figure 1

Back to TopTop